TMO Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today completed its previously announced acquisition of Finesse Solutions, Inc., a leader in the development of scalable control automation systems and software for bioproduction. The business will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. Terms of the transaction were not disclosed.

Based in Santa Clara, California, Finesse Solutions is a leader in bioprocess management technology, generating approximately $50 million in revenue in 2016. Its proprietary Smart™ technology, which consists of sensors, controllers and software, is designed to optimize the bioproduction workflow. The company has been a technology partner of Thermo Fisher Scientific since 2013.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

EN
14/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Thermo Fisher Scientific Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Thermo Fisher Scientific Inc: 2 directors

Two Directors at Thermo Fisher Scientific Inc sold after exercising options/sold 5,696 shares at between 588.265USD and 594.420USD. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tra...

Moody's Ratings says Thermo Fisher's Clario acquisition expands clinic...

Moody's Ratings commented that Thermo Fisher Scientific Inc.'s (A3 positive) announcement that it entered into a definitive agreement to acquire privately held Clario Holdings, Inc. for $8.88 billion plus certain potential future payouts will add scale and earnings diversity and bolster capabilities...

Thermo Fisher Scientific Inc.: Clario acquisition expands clinical tri...

The acquisition is earnings accretive and enhances the value of services provided to research customers, while increasing leverage by about one-half turn.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch